Abstract: Systems, methods, and devices are disclosed for facilitating injection of a medicament using an automatic injection device. The automatic injection device includes a housing defining a confined inner space and having a length extending from a proximal end to a distal end along a longitudinal axis. A helical biasing member, or spring, is disposed in the confined inner space, and the spring has an inner diameter at a middle portion that is greater than an inner diameter at the terminal ends of the spring. A syringe plunger has a second bifurcated end extending into an inner bore of the spring. The bifurcated end includes two flexible arms that are able to flex inwardly and outwardly relative to the longitudinal axis within the inner bore of the spring while maintaining an annular gap between the syringe plunger and the spring.

Abstract: Systems, methods, and devices are disclosed for facilitating injection of a medicament using an automatic injection device. The automatic injection device includes a housing defining a confined inner space and having a length extending from a proximal end to a distal end along a longitudinal axis. A helical biasing member, or spring, is disposed in the confined inner space, and the spring has an inner diameter at a middle portion that is greater than an inner diameter at the terminal ends of the spring. A syringe plunger has a second bifurcated end extending into an inner bore of the spring. The bifurcated end includes two flexible arms that are able to flex inwardly and outwardly relative to the longitudinal axis within the inner bore of the spring while maintaining an annular gap between the syringe plunger and the spring.

Abstract: Exemplary embodiments provide firing mechanism assemblies that minimize or eliminate a misfire of an automatic injection device that causes a delay in the delivery of an injection. Exemplary embodiments provide automatic injection devices including firing mechanism assemblies that minimize or eliminate a misfire that causes a delay in the delivery of an injection. Exemplary embodiments provide methods for minimizing or eliminating misfire that causes a delay in delivery of an injection in automatic injection devices. Exemplary embodiments provide methods for using automatic injection devices that are free of a misfire that causes delay in delivery of a therapeutic substance into a patient's body.

Abstract: Exemplary embodiments provide firing mechanism assemblies that minimize or eliminate a misfire of an automatic injection device that causes a delay in the delivery of an injection. Exemplary embodiments provide automatic injection devices including firing mechanism assemblies that minimize or eliminate a misfire that causes a delay in the delivery of an injection. Exemplary embodiments provide methods for minimizing or eliminating misfire that causes a delay in delivery of an injection in automatic injection devices. Exemplary embodiments provide methods for using automatic injection devices that are free of a misfire that causes delay in delivery of a therapeutic substance into a patient's body.

Abstract: Exemplary embodiments provide firing mechanism assemblies that minimize or eliminate a misfire of an automatic injection device that causes a delay in the delivery of an injection. Exemplary embodiments provide automatic injection devices including firing mechanism assemblies that minimize or eliminate a misfire that causes a delay in the delivery of an injection. Exemplary embodiments provide methods for minimizing or eliminating misfire that causes a delay in delivery of an injection in automatic injection devices. Exemplary embodiments provide methods for using automatic injection devices that are free of a misfire that causes delay in delivery of a therapeutic substance into a patient's body.

Abstract: A process for producing high purity 6,12-dideoxyerythromycin A using recombinant DNA technology is disclosed. The erythromycin producing strain, Saccharopolyspora erythraea, lacking the erythromycin C-12 and C-6 hydroxylases produces a mixture of 6,12-dideoxyerythromycin A and the precursor molecule, 6-deoxyerythromycin D. To achieve conversion of the precursor to the final product, a second copy of eryG is inserted into a non-essential region of the Sac. erythraea chromosome resulting in high purity 6,12-dideoxyerythromycin A.

Abstract: A process for producing high purity 6,12-dideoxyerythromycin A using recombinant DNA technology is disclosed. The erythromycin producing strain, Saccharopolyspora erythraea, lacking the erythromycin C-12 and C-6 hydroxylases produces a mixture of 6,12-dideoxyerythromycin A and the precursor molecule, 6-deoxyerythromycin D. To achieve conversion of the precursor to the final product, a second copy of eryG is inserted into a non-essential region of the Sac. erythraea chromosome resulting in high purity 6,12-dideoxyerythromycin A.